Mycophenolate Mofetil
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
- Mycophenolate Mofetil
- Mycophenolate Mofetil: From Organ Transplant Rejection Prophylaxis to HIV Infectious Disease
Mycophenolate Mofetil: From Organ Transplant Rejection Prophylaxis to HIV Infectious Disease
One-Sentence Summary
Mycophenolate mofetil (MMF) is an established immunosuppressant used to prevent acute rejection after renal, hepatic and cardiac transplantation. The TxGNN model predicts it may also be effective for HIV Infectious Disease, with 10 clinical trials and 20 publications currently identified, though the evidence is dated, mixed and largely inconclusive.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Organ transplant rejection prophylaxis (renal/hepatic/cardiac) — not captured in this evidence pack; based on established clinical use of mycophenolate mofetil |
| Predicted New Indication | HIV Infectious Disease |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L2 |
| UK Market Status | Not marketed (per this evidence pack) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, mycophenolate mofetil is the prodrug of mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) that blocks de novo purine (guanosine) synthesis in lymphocytes. Its efficacy in preventing organ transplant rejection has been established for decades through suppression of alloreactive T- and B-lymphocyte proliferation.
The link between transplant rejection prophylaxis and HIV infection lies in this same antiproliferative mechanism: by depleting intracellular guanosine triphosphate (GTP) pools, MPA limits proliferation of activated CD4+ T cells — the primary cellular target and reservoir for HIV replication — while also appearing to potentiate the intracellular activation of certain nucleoside reverse transcriptase inhibitors (e.g. abacavir, didanosine). Several early pilot studies (2001–2007) explored MMF as an adjunct to antiretroviral therapy on this dual rationale.
However, mechanistic plausibility has not translated into robust clinical evidence: the relevant trials are small, mostly from the early-to-mid 2000s, and several were withdrawn, terminated, or left with unknown outcome status (e.g. the Phase 4 MAN2 study, NCT00120419). This suggests the concept has been explored but not established as a viable therapeutic strategy.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00120419 | Phase 4 | Unknown | 90 | MAN2 study — MMF evaluated for chronic immune hyperactivation and CD4+ decline in untreated HIV-1 infection; status unknown, no published results |
| NCT00038272 | Phase 1/2 | Completed | 56 | Randomised, double-blind, placebo-controlled trial of DAPD vs DAPD+MMF in treatment-experienced HIV patients |
| NCT00247494 | Phase 4 | Unknown | 90 | MAN2 substudy assessing MMF’s effect on cardiovascular surrogate markers in HIV-1 infection |
| NCT00021489 | Phase 1/2 | Withdrawn | 0 | Planned trial of MMF as adjunct to abacavir in treatment-experienced HIV patients; withdrawn, enrolment=0 |
| NCT00009009 | Phase 2 | Completed | 10 | Renal transplantation feasibility in HIV-infected patients with ESRD; MMF used as standard anti-rejection therapy, not tested for antiviral effect |
| NCT01453192 | Phase 3 | Completed | 27 | Multicentre follow-up after renal transplantation in HIV-1 patients; MMF part of standard immunosuppressive regimen |
| NCT00112593 | N/A | Completed | 5 | Allogeneic HSCT with MMF/cyclosporine immunosuppression in HIV+ patients; MMF used as standard post-transplant agent, not an HIV-directed intervention |
| NCT02793544 | Phase 2 | Completed | 80 | HLA-mismatched unrelated donor BMT with MMF for GVHD prophylaxis in haematologic malignancies; not HIV-specific |
| NCT01288131 | Phase 3 | Terminated | 8 | RCT of cyclosporine+MMF vs cyclophosphamide+prednisolone for anti-EPO PRCA; unrelated to HIV indication |
| NCT06869265 | Phase 2 | Recruiting | 56 | Haploidentical HSCT conditioning regimen in elderly high-risk AML; MMF used for GVHD prophylaxis, not HIV-focused |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15213566 | 2004 | Randomised pilot study | J Acquir Immune Defic Syndr | MMF added during HAART interruption in chronic HIV-1 infection; assessed immune response and plasma/lymphatic viral load |
| 17017956 | 2006 | Review | Curr Top Med Chem | Reviews immunosuppressive drugs, including MMF, as adjuncts targeting chronic immune activation in HIV disease |
| 12352149 | 2002 | Cohort | J Acquir Immune Defic Syndr | MMF added to abacavir-containing ART depleted intracellular dGTP and was associated with decreased plasma HIV-1 RNA |
| 15355127 | 2004 | Cohort | Clin Pharmacokinet | MMF’s effect on antiretroviral drug pharmacokinetics and intracellular nucleoside triphosphate pools |
| 15871638 | 2005 | Cohort | Clin Pharmacokinet | Pharmacokinetics/pharmacodynamics of low-dose MMF combined with abacavir, efavirenz and nelfinavir in HIV-infected patients |
| 11391161 | 2001 | Cohort (pilot) | J Acquir Immune Defic Syndr | Open-label pilot of MMF as component of therapy for multidrug-resistant HIV-1 infection in heavily treatment-experienced patients |
| 17885292 | 2007 | Cohort | AIDS | Safety, tolerability and antiretroviral activity of DAPD with or without MMF in drug-resistant HIV infection |
| 15353978 | 2004 | Cohort | AIDS | HAART with or without MMF in treatment-naive HIV-1 patients; effect on plasma RNA decay and latent reservoir |
| 16379601 | 2005 | Cohort | AIDS Res Hum Retroviruses | No detrimental immunological effects observed with MMF plus HAART in treatment-naive acute/chronic HIV-1 patients |
| 41118390 | 2025 | Preclinical | J Clin Invest | Explores selective targeting of clonally expanded HIV-infected CD4+ T cells using antiproliferative drugs; conceptually related to MMF’s mechanism |
UK Market Information
No marketing authorisation records for mycophenolate mofetil were found in this evidence pack, and market status is recorded as “not marketed.” This should be verified independently against the current MHRA product register, as mycophenolate mofetil-containing products are known to be authorised in the UK for transplant indications under the BNF immunosuppressant classification.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: This evidence pack flags a blocking data gap — TFDA/MHRA labelling warnings and contraindications are not yet available, which prevents a preliminary safety assessment (Stage S1) for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale: Although the IMPDH-inhibition mechanism is biologically plausible for HIV infection and several pilot trials (L2 evidence) explored this rationale, most trials are small, over 15 years old, and a number were withdrawn, terminated, or left with unknown outcomes (including the pivotal Phase 4 MAN2 study). Combined with a blocking gap in safety labelling data, the evidence does not yet support progression beyond exploratory research.
To proceed, the following is needed:
- MHRA/SmPC safety labelling data (warnings and contraindications) — currently blocking
- Confirmed mechanism of action documentation (e.g. via DrugBank)
- Updated outcome/completion data for the MAN2 study (NCT00120419) and its cardiovascular substudy (NCT00247494)
- Contemporary trial data, as most direct evidence predates 2010
- Verification of current UK marketing authorisation status for mycophenolate mofetil products
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.